N2OFF Rebrands as Nexentis, Pivots to AI-Driven Biotech
Event summary
- N2OFF Inc. rebrands as Nexentis Technologies, effective February 26, 2026, with NASDAQ ticker changing to NXTS.
- Company pivots from cleantech to AI-driven biotech, focusing on mitochondrial biology and inflammatory metabolic diseases.
- Acquisition of MitoCareX Bio Ltd. in October 2025 marked the strategic shift, integrating MITOLINE™ algorithm for drug discovery.
- Nexentis aims to build a diversified pipeline of first-in-class small-molecule programs while managing solar energy investments as non-core assets.
- Preliminary in vitro data shows MITOLINE™-derived candidates reduce pro-inflammatory markers in human immune cells.
The big picture
Nexentis' rebranding reflects a broader industry trend of biotech companies leveraging AI and computational platforms to accelerate drug discovery. The pivot from cleantech to biotech positions the company to capitalize on the growing market for precision oncology and inflammatory metabolic disease treatments, projected to exceed $120 billion by 2030. The strategic shift also highlights the increasing convergence of technology and life sciences, as companies seek to optimize R&D through data-driven approaches.
What we're watching
- Pipeline Progress
- Whether Nexentis can advance preclinical candidate nominations and translate in silico and in vitro discoveries into development-ready assets.
- Market Alignment
- How the rebranding enhances strategic clarity and improves alignment with R&D priorities in the biotech and pharmaceutical ecosystem.
- Execution Risk
- The pace at which Nexentis can validate its MITOLINE™ platform and secure partnerships to support its diversified pipeline.
Related topics